Clinical and light microscopy confirmed scabies
Conditions
Brief summary
Percentage of subjects (Score 0; see below) with Complete cure rate (CCR) at Visit 1 (week 1)
Detailed description
Percentage of subjects (Score 0; see below) with Complete cure rate (CCR) at Visit 2 (week 2), Percentage of Subjects with score 0 or 1 at week 1, Percentage of subjects with CCR at week 2, Percentage of subjects with score 0 or 1 at week 2, Subjective evaluation of itching at week 1 and 2, Percentage of treatment failure at week 1 and week 2 (treatment failure is defined as: no improvement at all of itching intensity and skin lesions count and/or appearance of new lesions), Safety and Tolerability endpoints: (at week 1, week 2) - Evaluation and recording of spontaneous reported adverse events - Blood pressure monitoring - Heart rate
Interventions
DRUGSCABIACID 5% crema
DRUGIVERMECTINA GIULIANI 3 mg compresse
Sponsors
Giuliani S.p.A.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects (Score 0; see below) with Complete cure rate (CCR) at Visit 1 (week 1) | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of subjects (Score 0; see below) with Complete cure rate (CCR) at Visit 2 (week 2), Percentage of Subjects with score 0 or 1 at week 1, Percentage of subjects with CCR at week 2, Percentage of subjects with score 0 or 1 at week 2, Subjective evaluation of itching at week 1 and 2, Percentage of treatment failure at week 1 and week 2 (treatment failure is defined as: no improvement at all of itching intensity and skin lesions count and/or appearance of new lesions), Safety and Tolerability endpoints: (at week 1, week 2) - Evaluation and recording of spontaneous reported adverse events - Blood pressure monitoring - Heart rate | — |
Countries
Italy
Outcome results
None listed